Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis
- 30 July 2025
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (12) , e1065-e1076
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension StudyActa Haematologica, 2023
- Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysisAnnals of Hematology, 2022
- The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United StatesClinical Therapeutics, 2020
- Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialThe Lancet Haematology, 2018
- Treatment of Myelodysplastic Syndrome with Thrombomimetic DrugsSeminars in Hematology, 2015
- Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopeniaCancer, 2014
- The biology of thrombopoietin and thrombopoietin receptor agonistsInternational Journal of Hematology, 2013
- Thrombocytopenia in Patients With Myelodysplastic SyndromesSeminars in Hematology, 2010
- Development of thrombopoietin receptor agonists for clinical useJournal of Thrombosis and Haemostasis, 2009
- The incidence and impact of thrombocytopenia in myelodysplastic syndromesCancer, 2007